Loading
companiesCompany
ARTBIO
ARTBIO makes cancer treatments that deliver short-range alpha radiation from lead-212 directly to tumour cells, starting with prostate cancer. Its first medicine is in early human trials, currently paused by the company while it reviews data.
Overview
ARTBIO, Inc. (Cambridge, Massachusetts, with engineering and manufacturing in Oslo) develops a new class of 212Pb alpha radioligand therapies (ARTs), together with its AlphaDirect isotope production technology and manufacturing ecosystem. The company was founded in 2021 by Roy Larsen and Øyvind Bruland, the inventors of Xofigo, with F-Prime and Radforsk. The lead asset AB001, a PSMA-targeted 212Pb radioligand for metastatic castration-resistant prostate cancer, is in the phase 1 ARTISAN trial; two cohorts (177Lu-PSMA naive and 177Lu-PSMA experienced) were dosed in January 2026, and in April 2026 the company implemented a voluntary clinical hold of ARTISAN. Jonathan Freeman was appointed interim CEO in July 2026. Further programmes include 212Pb antibody conjugates and the HEARTS discovery platform. ARTBIO raised a USD 90 million Series A in December 2023 and about USD 132 million in July 2025, according to Endpoints News.
Headquarters
Cambridge, MA, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · Endpoints reports a USD 132 million raise in July 2025; the Series B label comes from the PR Newswire headline seen in search results, not from a fetched page | 2025 | $132M | endpoints.news |
| Series A | 2023 | $90M | endpoints.news |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Stage
Startup
Website
Founded
2021
Notes
top- Endpoints article bodies are paywalled; amounts come from the visible headline and lede.
Similar pages
- CompanyAbdera Therapeutics
Shares Endpoints News, Targeted alpha therapy, Radioligand therapy (beta emitters).
- CompanyAriceum Therapeutics
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- CompanyPOINT Biopharma
Shares PSMA, Radioligand therapy (beta emitters), Prostate cancer.
- TrialA Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Shares PSMA, Prostate cancer.
- PersonJeremie Calais
Shares PSMA, Radioligand therapy (beta emitters), Prostate cancer.
- CompanyConvergent Therapeutics
Shares Targeted alpha therapy, PSMA, Prostate cancer.
- TechnologyAstatine-211 alpha therapy
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Prostate cancer.
- TrialA Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Shares PSMA, Prostate cancer.